2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension

Chih Hsin Hsu, Wan Jing Ho, Wei Chun Huang, Yu Wei Chiu, Tsu Shiu Hsu, Ping Hung Kuo, Hsao Hsun Hsu, Jia Kan Chang, Chin Chang Cheng, Chao Lun Lai, Kae Woei Liang, Shoa Lin Lin, Shih Hsien Sung, Wei Chuan Tsai, Ken Pen Weng, Kai Sheng Hsieh, Wei Hsian Yin, Shing Jong Lin, Kuo Yang Wang

研究成果: Review article

10 引文 斯高帕斯(Scopus)

摘要

Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a mean pulmonary arterial pressure exceeding 25 mmHg at rest. According to the recent classifications, it is grouped into pulmonary arterial hypertension (PAH), heart-related, lung-related, thromboembolic, and miscellaneous PH. In the past two decades, tremendous advances have occurred in the field of PH. These include (1) development of clinical diagnostic algorithm and a monitoring strategy dedicated to PAH, (2) defining strong rationales for screening at-risk populations, (3) advent of pulmonary specific drugs which makes PAH manageable, (4) recognition of needs of having proper strategy of combining existing pulmonary specific drugs, and/or potential novel drugs, (5) pursuit of clinical trials with optimal surrogate endpoints and study durations, (6) recognition of critical roles of PH/right ventricular function, as well as interdependence of ventricles in different conditions, especially those with various phenotypes of heart failure, and (7) for rare diseases, putting equal importance on carefully designed observation studies, various registries, etc., besides double blind randomized studies. In addition, ongoing basic and clinical research has led to further understanding of relevant physiology, pathophysiology, epidemiology and genetics of PH/PAH. This guidelines from the working group of Pulmonary Hypertension of the Taiwan Society of Cardiology is to provide updated guidelines based on the most recent international guidelines as well as Taiwan's domestic research on PH. The guidelines aremainly for themanagement of PAH (Group 1); however themajority of content can be helpful for managing other types of PH.

原文English
頁(從 - 到)401-444
頁數44
期刊Acta Cardiologica Sinica
30
發行號5
出版狀態Published - 2014 九月 1

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

指紋 深入研究「2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension」主題。共同形成了獨特的指紋。

  • 引用此

    Hsu, C. H., Ho, W. J., Huang, W. C., Chiu, Y. W., Hsu, T. S., Kuo, P. H., Hsu, H. H., Chang, J. K., Cheng, C. C., Lai, C. L., Liang, K. W., Lin, S. L., Sung, S. H., Tsai, W. C., Weng, K. P., Hsieh, K. S., Yin, W. H., Lin, S. J., & Wang, K. Y. (2014). 2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension. Acta Cardiologica Sinica, 30(5), 401-444.